Controlled and efficient cell and tissue delivery remains an enormous technical challenge, limiting many biotechnology and health applications. This project aims to increase the local delivery and cellular uptake of siRNA molecules. This will be achieved by incorporation within biodegradable polyester/polyhexanide nanoparticles. The siRNA will target tyrosine kinase, providing a novel and specific biological for inhibition of VEGF. Three work packages include: 1) siRNA loading nanoparticles and stability studies, 2) cell delivery, efficacy and mechanism of action studies in liver and vascular tumour cell lines 3) Tissue delivery, efficacy and mechanism of action studies in an ex vivo tissue perfusion model.
Y. Pylayeva-Gupta, E. Grabocka, D. Dar-Sagi, RAS Oncogenes: Weaving a Tumorigenic web, Nature Reviews Cancer, 2010 11, 761-774
G. Verdine, L. Walensky, The Challenge of Drugging Undruggable Targets in Cancer: Lessons Learned from Targeting BCL-2 Family Members, Clin Cancer Re 2007;13: 7264
N. Wang, K. Burugapalli, W. Song, F. Moussy, A. Ray, Y. Zheng, Electrospun Polyurethane Nano-fibrous Coating for Glucose Biosensor, Biomaterials, 2013, 34(4):888-901
L. Good, K. Chindera, V. Gburcik, patent, WO/2013/054123- METHODS
Mr Duncan Spalding. PhD, 2006, UCL, A novel ex vivo perfusion model for the assessment of chemotherapy for colorectal metastases. Awarded with distinction